Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Cross-bridge Cycle01:26

Cross-bridge Cycle

117.9K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.9K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

723
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
723
Muscle Contraction01:10

Muscle Contraction

6.7K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibro-adipogenic progenitors enhance functional and structural properties of human 3D tissue engineered skeletal muscles.

Journal of tissue engineering·2026
Same author

Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study.

Journal of medical economics·2026
Same author

Test-Retest Reliability of Remote Assessments in Patients With Myotonic Dystrophy Type 1.

Neurology·2026
Same author

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

The New England journal of medicine·2026
Same author

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases·2026
Same author

A pilot study using actigraphy to examine activity performance and its relationship with activity capacity in adults with facioscapulohumeral muscular dystrophy.

Journal of neuromuscular diseases·2025
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.5K

Myotonic Dystrophy.

Johanna I Hamel

    Continuum (Minneapolis, Minn.)
    |December 20, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Myotonic dystrophy type 1 and 2 are genetic disorders affecting multiple organs. Advances in understanding DM1 and DM2 molecular mechanisms offer new therapeutic opportunities for improved patient care and quality of life.

    More Related Videos

    Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
    14:10

    Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

    Published on: January 31, 2013

    33.2K
    Immunolabelling Myofiber Degeneration in Muscle Biopsies
    06:37

    Immunolabelling Myofiber Degeneration in Muscle Biopsies

    Published on: December 5, 2019

    8.9K

    Related Experiment Videos

    Last Updated: Aug 16, 2025

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
    09:39

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

    Published on: July 29, 2016

    15.5K
    Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
    14:10

    Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

    Published on: January 31, 2013

    33.2K
    Immunolabelling Myofiber Degeneration in Muscle Biopsies
    06:37

    Immunolabelling Myofiber Degeneration in Muscle Biopsies

    Published on: December 5, 2019

    8.9K

    Area of Science:

    • Neurology
    • Genetics
    • Molecular Biology

    Background:

    • Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are inherited disorders impacting skeletal muscle, smooth muscle, cardiac, and neurological systems.
    • The multisystemic nature and significant variability of myotonic dystrophy present challenges in clinical management and research.
    • Understanding the molecular basis of DM1 and DM2 is crucial for developing effective treatments.

    Approach:

    • This review synthesizes recent findings on the clinical manifestations and molecular underpinnings of DM1 and DM2.
    • It highlights advances in characterizing the diverse phenotypes associated with these conditions.
    • The focus is on diagnosis, management, and the implications of new research for patient care.

    Key Points:

    • Recent studies have elucidated the molecular mechanisms driving DM1 and DM2, revealing potential therapeutic targets.
    • Significant progress has been made in understanding the complex and variable clinical presentations, including cardiac and respiratory issues.
    • Several DM1 therapeutics are now in clinical trials, indicating a promising future for targeted treatments.

    Conclusions:

    • Continued research into the molecular and clinical aspects of DM1 and DM2 is essential.
    • Accurate monitoring of the variable clinical features is vital for optimizing patient care and quality of life.
    • Developing targeted therapies based on a deeper understanding of disease mechanisms holds promise for treating myotonic dystrophy.